. .

 
Zuruecksetzen

Suchergebnis - BOSTON SCIENTIFIC CORP. REGISTERED SHARES DL -,01

Zeit Titel
08.05 22:01dpa-AFX: *BOSTON SCIENTIFIC ELECTS CHERYL PEGUS TO BOARD OF DIRECTORS
24.04 12:54dpa-AFX: ROUNDUP: Boston Scientific Boosts FY24 Outlook
24.04 12:36dpa-AFX: *BOSTON SCIENTIFIC PROJECTS FY EPS TO BE $1.43 TO $1.48, ADJ. EPS OF $2.29 TO $2.34
24.04 12:36dpa-AFX: *BOSTON SCIENTIFIC EXPECTS Q2 EPS TO BE $0.35 TO $0.37 AND ADJ EPS $0.57 TO $0.59
24.04 12:35dpa-AFX: *BOSTON SCIENTIFIC Q1 ATTRIBUTABLE NET INCOME $495 MLN OR $0.33/SHR VS $300 MLN OR $0.21/SHR PRIOR YEAR
24.04 12:34dpa-AFX: *BOSTON SCIENTIFIC Q1 NET SALES $3.856 BLN, UP 13.8% ON REPORTED BASIS, 15.0% ON OPERATIONAL1 BASIS
24.04 12:33dpa-AFX: Boston Scientific Corp Q1 Profit Increases, beats estimates
24.04 12:32dpa-AFX: *BOSTON SCIENTIFIC Q1 ADJ. EPS RISES TO $0.56 FROM $0.47 A YEAR AGO
24.04 12:01dpa-AFX: Boston Scientific Q1 24 Earnings Conference Call 8:00 AM ET
08.04 06:08dpa-AFX: *BOSTON SCIENTIFIC BEGINS NAVIGATE-PF STUDY OF FARAWAVE NAV PULSED FIELD ABLATION CATHETER AND FARAVIEWT SOFTWARE MODULE
04.04 22:13MÄRKTE USA/Börsen deutlich im Minus - Warten auf US-Arbeitsmarktbericht
04.04 18:15MÄRKTE USA/Wall Street mit Aufschlägen
04.04 15:41MÄRKTE USA/Fester - Warten auf US-Arbeitsmarktbericht
04.04 14:52MÄRKTE USA/Etwas fester - Warten auf Arbeitsmarktbericht
04.04 14:19dpa-AFX: Boston Scientific Says FTC Issues Second Request Amid Boston Scientific And Axonics Merge Review
04.04 13:58dpa-AFX: *FTC ISSUES SECOND REQUEST TO BOSTON SCIENTIFIC AND AXONICS REGARDING MERGE REVIEW
01.03 13:22dpa-AFX: Boston Scientific: FDA Approves AGENT Drug-Coated Balloon
01.03 12:59dpa-AFX: *BOSTON SCIENTIFIC: FDA APPROVES AGENT DRUG-COATED BALLOON TO TREAT CORONARY ISR IN PATIENTS WITH CORONARY ARTERY DISEASE
31.01 12:57dpa-AFX: Boston Scientific Says FDA Approved FARAPULSE Pulsed Field Ablation System
31.01 12:55dpa-AFX: Boston Scientific Q4 Results Top View; Sees Q1 Adj. EPS In Line Or Below Market; Stock Up

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH